<DOC>
	<DOCNO>NCT00002752</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy treat patient primary metastatic brain cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Primary Metastatic Brain Cancers</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect intracranial iodine I 131 label anti-tenascin monoclonal antibody 81C6 patient primary metastatic anaplastic glioma . - Determine objective therapeutic response patient treat regimen . OUTLINE : This dose escalation study iodine I 131 label anti-tenascin monoclonal antibody 81C6 ( MOAB 81C6 ) . Patients stratify prior external beam radiotherapy ( yes v ) . Patients receive iodine I 131 label MOAB 81C6 intraventricularly follow unlabeled MOAB 81C6 intraventricularly . Cohorts 3-6 patient receive escalate dos iodine I 131 label MOAB 81C6 maximum tolerate dose determine . The MTD define high dose precede 3 6 patient experience dose-limiting toxicity . Patients follow monthly 2 year , every 2 month 2 year , every 3 month thereafter . PROJECTED ACCRUAL : A total 3-6 patient per cohort accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary metastatic malignant supratentorial anaplastic glioma Newly diagnose recurrent No diffusely infiltrate multifocal tumor No tumor subependymal spread Resection glioma placement intralesional catheter surgical cavity require study Measurable lesion enhance CT scan MRI No measurable enhance lesion great 1.0 cm beyond cavity margin Neoplastic cell reactivity tenascin demonstrate immunohistology either polyclonal rabbit antibody monoclonal murine antibody PATIENT CHARACTERISTICS : Age : 3 Performance status : Karnofsky 50100 % Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL AST le 1.5 time normal Alkaline phosphatase less 1.5 time normal Renal : Creatinine le 1.2 mg/dL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior chemotherapy unless unequivocal evidence tumor progression Endocrine therapy : Corticosteroids allow low possible dose dose stable least 10 day prior entry Radiotherapy : At least 3 month since prior radiotherapy site measurable disease unless unequivocal evidence tumor progression Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>